Department of Clinical Pharmacy and Pharmacotherapy Institute of PharmacyMartin-Luther-University Halle-Wittenberg Halle (Saale) Germany.
J Am Heart Assoc. 2022 Jun 21;11(12):e025119. doi: 10.1161/JAHA.121.025119. Epub 2022 Jun 14.
Background The small GTPase RhoA (Ras homolog gene family, member A) regulates a variety of cellular processes, including cell motility, proliferation, survival, and permeability. In addition, there are reports indicating that RhoA-ROCK (rho associated coiled-coil containing protein kinase) activation is essential for VEGF (vascular endothelial growth factor)-mediated angiogenesis, whereas other work suggests VEGF-antagonistic effects of the RhoA-ROCK axis. Methods and Results To elucidate this issue, we examined human umbilical vein endothelial cells and human coronary artery endothelial cells after stable overexpression (lentiviral transduction) of constitutively active (G14V/Q63L), dominant-negative (T19N), or wild-type RhoA using a series of in vitro angiogenesis assays (proliferation, migration, tube formation, angiogenic sprouting, endothelial cell viability) and a human umbilical vein endothelial cells xenograft assay in immune-incompetent NOD gamma mice in vivo. Here, we report that expression of active and wild-type RhoA but not dominant-negative RhoA significantly inhibited endothelial cell proliferation, migration, tube formation, and angiogenic sprouting in vitro. Moreover, active RhoA increased endothelial cell death in vitro and decreased human umbilical vein endothelial cell-related angiogenesis in vivo. Inhibition of RhoA by C3 transferase antagonized the inhibitory effects of RhoA and strongly enhanced VEGF-induced angiogenic sprouting in control-treated cells. In contrast, inhibition of RhoA effectors ROCK1/2 and LIMK1/2 (LIM domain kinase 1/2) did not significantly affect RhoA-related effects, but increased angiogenic sprouting and migration of control-treated cells. In agreement with these data, VEGF did not activate RhoA in human umbilical vein endothelial cells as measured by a Förster resonance energy transfer-based biosensor. Furthermore, global transcriptome and subsequent bioinformatic gene ontology enrichment analyses revealed that constitutively active RhoA induced a differentially expressed gene pattern that was enriched for gene ontology biological process terms associated with mitotic nuclear division, cell proliferation, cell motility, and cell adhesion, which included a significant decrease in VEGFR-2 (vascular endothelial growth factor receptor 2) and NOS3 (nitric oxide synthase 3) expression. Conclusions Our data demonstrate that increased RhoA activity has the potential to trigger endothelial dysfunction and antiangiogenic effects independently of its well-characterized downstream effectors ROCK and LIMK.
小 GTP 酶 RhoA(Ras 同源基因家族,成员 A)调节多种细胞过程,包括细胞运动、增殖、存活和通透性。此外,有报道表明 RhoA-ROCK(rho 相关卷曲螺旋蛋白激酶)的激活对于 VEGF(血管内皮生长因子)介导的血管生成是必不可少的,而其他工作则表明 RhoA-ROCK 轴具有拮抗 VEGF 的作用。
为了解决这个问题,我们使用一系列体外血管生成试验(增殖、迁移、管形成、血管生成发芽、内皮细胞活力)和体内免疫缺陷 NOD γ 小鼠的人脐静脉内皮细胞异种移植试验,在稳定过表达(慢病毒转导)组成型激活(G14V/Q63L)、显性负(T19N)或野生型 RhoA 的人冠状动脉内皮细胞中检查了 RhoA-ROCK 轴的作用。在此,我们报告说,表达活性和野生型 RhoA 但不是显性负 RhoA 可显著抑制体外内皮细胞增殖、迁移、管形成和血管生成发芽。此外,活性 RhoA 增加了体外内皮细胞死亡,并减少了体内人脐静脉内皮细胞相关的血管生成。C3 转移酶抑制 RhoA 可拮抗 RhoA 的抑制作用,并强烈增强对照处理细胞中 VEGF 诱导的血管生成发芽。相比之下,抑制 RhoA 效应物 ROCK1/2 和 LIMK1/2(LIM 结构域激酶 1/2)并没有显著影响 RhoA 相关作用,但增加了对照处理细胞的血管生成发芽和迁移。与这些数据一致,通过基于 Förster 共振能量转移的生物传感器测量,VEGF 并未在人脐静脉内皮细胞中激活 RhoA。此外,全转录组和随后的生物信息学基因本体富集分析表明,组成型激活的 RhoA 诱导了一个差异表达的基因模式,该模式富含与有丝分裂核分裂、细胞增殖、细胞运动和细胞黏附相关的基因本体生物学过程术语,其中包括血管内皮生长因子受体 2 (VEGFR-2) 和一氧化氮合酶 3 (NOS3) 表达的显著下降。
我们的数据表明,增加的 RhoA 活性有可能独立于其特征下游效应物 ROCK 和 LIMK 引发内皮功能障碍和抗血管生成作用。